Tixagevimab/AZD8895 represents a novel treatment approach utilizing two monoclonal immunoglobulins. Specifically, these agents function by precisely binding to the spike area of the SARS-CoV-2 virus, preventing its ability to fuse with human cells. This obstruction of viral access essentially deacti